← Leaderboards
Livia Garzia
University Of California, San Francisco
$1,301,003
Attributed
$3,903,008
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $819.4K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,903,008 · 1
By mechanism
R01$3,903,008 · 1
Top collaborators
- Michael D. Taylor6 shared
- William A Weiss6 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- William A Weiss$31,543,847
- Michael D. Taylor$7,522,868
- Valerie Marie Weaver$26,171,723
- Laura J Van't Veer$11,693,569
- Nola M. Hylton$19,153,972
Others in their field
Other Emerging Leaders on “Childhood Cancer Mortality”
- Kimberly Ann Miller · University Of Southern California$6,920,441
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$6,865,597
- David M. Ashley · Duke University$6,378,870
- Phd, Ralph Parchment · Leidos Biomedical Research, Inc.$5,367,461
- Tara M Brinkman · St. Jude Children'S Research Hospital$4,421,915
- Paul Northcott · St. Jude Children'S Research Hospital$4,034,294
Research focus
Childhood Cancer MortalityAntibodiesAttenuatedBiomarker DevelopmentBindingBlocking AntibodiesBloodBiological MarkersBrainBrain NeoplasmsCancer EtiologyCarcinomaCause Of DeathCcl2 GeneCellsCellular BiologyBlood CirculationCerebrospinal FluidCessation Of LifeChemokineChemotherapyChildChildhoodChildhood Malignant Brain Tumor
Grant awards (6)
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$630,753
R01 · FY2025 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$157,894
R01 · FY2025 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$749,215
R01 · FY2024 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$772,874
R01 · FY2023 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$772,874
R01 · FY2022 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$819,398
R01 · FY2021 · CA